Table S3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

This is a Experimental Study study.

Key Points

Therapeutic efficacy was observed with IPH5201 in treating advanced solid tumors, indicating potential in immunotherapy.
Special attention is needed for thromboembolic events reported during treatment with anti-cd39 mAb and durvalumab.
The combination therapy of IPH5201 with durvalumab shows promise, suggesting a new approach in advanced cancer treatment.
Further evaluation of the safety profile of thromboembolic events is recommended to ensure patient safety.

We only have this paper's title and publication details.

Analysis indicates therapeutic efficacy of anti-cd39 mAb in advanced solid tumors, highlighting safety concerns regarding thromboembolic events.

TEAEs of special interest for IPH5201: thromboembolic events.

No takes yet. Share an insight, caveat, or question.

Powderly et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share